![]() |
市場調查報告書
商品編碼
1447059
到 2030 年輸血診斷市場預測:按產品、應用、最終用戶和地區進行的全球分析Blood Transfusion Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球輸血診斷市場規模將達到 48 億美元,預計到 2030 年將達到 85 億美元,預測期內年複合成長率為 8.5%。
市場透過檢測感染疾病、確定血型以及評估供血者和受血者之間的兼容性,在確保輸血的安全性和有效性方面發揮關鍵作用。這些診斷有助於識別潛在的病原體,例如愛滋病毒、B型肝炎、C型肝炎和梅毒,從而降低透過輸血感染的風險。此外,血型和交叉配血檢查可確保捐贈者和受血者血液的相容性,並最大限度地減少輸血過程中副作用的可能性。
Medscape 2022 年 3 月發表的報導報告稱,美國A型血友病的盛行率為每 10 萬名男性 20.6 人。根據加拿大血友病協會 (CHS) 2022 年 2 月發表的報導,患有A型血友病的加拿大人總數估計為 3,100 人。
增加捐血篩檢計劃
隨著對公共衛生和安全標準的日益重視,旨在檢測可能損害捐捐血液完整性的感染疾病和其他健康狀況的捐血篩檢計畫普及。這些篩檢計畫採用先進的診斷技術,例如核酸檢測(NAT)、血清學和免疫檢測,來識別與捐血相關的潛在風險,並將透過輸血感染的可能性降至最低。
昂貴的設備和測試費用
輸血診斷在很大程度上依賴專業設備和先進的檢測,以確保輸血所捐血的安全性和適用性。從自動化分析儀到試劑和消耗品,這些工具的購買和維護成本高。診斷過程的複雜性需要熟練的人員進行操作和解釋,進一步增加了整體成本。然而,投資此類設備和進行測試的財務負擔可能會很大,特別是對於資源匱乏地區和開發中國家的醫療機構來說,這可能會限制他們提供全面輸血服務的能力。
醫療保健支出增加
隨著醫療保健支出的增加,對先進醫療技術和程序(包括輸血診斷)的需求也在增加。支出的增加使醫療機構能夠投資尖端設備和診斷工具,以確保輸血的安全性和有效性。此外,隨著醫療保健預算的擴大,人們越來越關注改善患者的治療結果和減少輸血相關的風險,例如輸血感染疾病和副作用。
限制獲得先進技術
準確且有效率的輸血診斷需要利用核酸增幅檢查(NAT)、次世代定序(NGS)和自動化血液篩檢系統等最尖端科技。許多地區,特別是開發中國家和偏遠地區,可能缺乏基礎設施、資源和訓練有素的人員來在醫療機構中實施這些先進技術。因此,及時、準確地進行血液篩檢和相容性測試的能力可能會受到影響,從而導致輸血感染疾病和輸血不相容等潛在風險。
與新冠病毒相關的併發症,例如嚴重呼吸困難和其他需要輸血支持的嚴重病症,增加了輸血的需求。需求的激增給確保血液製品安全性和相容性的診斷服務帶來了壓力。同時,與疫情相關的法規、對感染疾病的恐懼以及醫療服務的中斷導致捐血下降,影響了血液供應鏈。因此,輸血診斷公司面臨著維持充足存量基準、及時檢測捐血血液以及提供有效診斷以確保大流行不確定性。
血紅素密度計細分市場預計在預測期內規模最大
血紅蛋白密度計可快速、可靠地評估血紅蛋白濃度,協助篩檢捐血並確保輸血的安全性和有效性,因此預期血紅蛋白密度計細分市場將成為最大的細分市場。透過讓醫療保健專業人員快速測量血紅蛋白濃度,血紅蛋白密度計簡化了捐血過程,降低了輸血反應的風險,並改善了患者的整體治療結果。此外,這些設備攜帶且易於使用,可用於各種醫療保健環境,包括偏遠地區和資源有限的地區。
預計血型分析領域在預測期內年複合成長率最高。
預計血型領域在預測期內將出現最高的年複合成長率。準確的血型和交叉配血對於防止輸血期間的副作用非常重要。血型技術和方法的進步,包括自動化系統和分子檢測方法的引入,使醫療機構能夠有效地確定血型並篩檢不規則抗體。這顯著降低了輸血反應的風險並改善了患者的治療結果。此外,由於外科手術、創傷病例和慢性病的增加,對血液製品的需求不斷增加,進一步推動了輸血診斷市場的區域成長。
由於可支配收入增加、醫療基礎設施改善、健康意識提高和有利的報銷政策,北美地區在預測期內佔據最大佔有率。美國紅十字會估計,美國每年輸注 1,600 萬份血液成分。此外,該地區輸血感染率高和捐血意識不斷增強預計將刺激市場擴張。
隨著越來越多的貧血患者需要輸紅血球進行治療,預計亞太地區將長期持續成長,從而推動對輸血診斷的需求。由於血友病、癌症、血小板減少性疾病和慢性腎臟病(CKD) 等血液相關疾病的盛行率不斷上升,該地區對血液製品和輸血的整體需求很高。
According to Stratistics MRC, the Global Blood Transfusion Diagnostics Market is accounted for $4.8 billion in 2023 and is expected to reach $8.5 billion by 2030 growing at a CAGR of 8.5% during the forecast period. This market serves a critical role in ensuring the safety and efficacy of blood transfusions by detecting infectious diseases, identifying blood groups, and assessing compatibility between donors and recipients. These diagnostics help identify potential pathogens such as HIV, hepatitis B and C, and syphilis, reducing the risk of transfusion-transmitted infections. Additionally, blood typing and crossmatching tests ensure compatibility between donor and recipient blood, minimizing the likelihood of adverse reactions during transfusions.
According to an article published by Medscape on March 2022, it was reported that the prevalence of Hemophilia A is 20.6 cases per 100,000 males in the United States. According to an article published by the Canadian Hemophilia Society (CHS) in February 2022, it was reported that the total number of Canadian suffering from Hemophilia A and B is estimated to be 3,100.
Rise in blood donor screening programs
With an increasing emphasis on public health and safety standards, blood donor screening programs have become more widespread, aiming to detect infectious diseases and other health conditions that could compromise the integrity of donated blood. These screening programs employ advanced diagnostic technologies such as nucleic acid testing (NAT), serological testing, and immunoassays to identify potential risks associated with donated blood, thus minimizing the chances of transfusion-transmitted infections.
High cost of equipment and tests
Blood transfusion diagnostics rely heavily on specialized equipment and sophisticated tests to ensure the safety and compatibility of donated blood for transfusion. These tools, ranging from automated analyzers to reagents and consumables, incur substantial expenses in procurement and maintenance. The complexity of diagnostic procedures necessitates skilled personnel for operation and interpretation, further adding to the overall costs. However, for healthcare facilities, especially in resource-constrained settings or developing countries, the financial burden of investing in such equipment and conducting tests can be prohibitive, limiting their capacity to offer comprehensive blood transfusion services.
Increasing healthcare expenditure
As healthcare expenditure rises, there is a corresponding increase in the demand for advanced medical technologies and procedures, including blood transfusion diagnostics. This heightened expenditure allows healthcare facilities to invest in state-of-the-art equipment and diagnostic tools for ensuring the safety and efficacy of blood transfusions. Moreover, as healthcare budgets expand, there's greater focus on improving patient outcomes and reducing the risks associated with blood transfusions, such as transfusion-transmitted infections and adverse reactions.
Limited access to advanced technologies
Access to cutting-edge technologies such as nucleic acid amplification tests (NAT), next-generation sequencing (NGS), and automated blood screening systems is essential for accurate and efficient blood transfusion diagnostics. In many regions, especially in developing countries or remote areas, healthcare facilities may lack the infrastructure, resources, or trained personnel to adopt these advanced technologies. As a result, the ability to perform timely and precise blood screening and compatibility testing may be compromised, leading to potential risks such as transfusion-transmitted infections or incompatible blood transfusions.
The demand for blood transfusions increased due to Covid-related complications, such as severe respiratory distress or other critical conditions requiring transfusion support. This surge in demand placed pressure on diagnostic services to ensure the safety and compatibility of blood products. On the other hand, pandemic-related restrictions, fear of infection, and disruptions in healthcare services led to reduced blood donations, affecting the blood supply chain. Consequently, blood transfusion diagnostic companies faced challenges in maintaining adequate inventory levels and ensuring timely testing for donated blood, thus intensifying the need for efficient diagnostic solutions and technologies to safeguard transfusion safety amidst the pandemic's uncertainties.
The hemoglobinometers segment is expected to be the largest during the forecast period
Hemoglobinometers segment is expected to be the largest during the forecast period, as it provides quick and reliable assessments of hemoglobin concentration, aiding in the screening of blood donors and ensuring the safety and efficacy of transfusions. By enabling healthcare professionals to rapidly determine hemoglobin levels, hemoglobinometers streamline the blood donation process, reducing the risk of transfusion reactions and improving overall patient outcomes. Additionally, these devices are portable and user-friendly, making them accessible in a variety of healthcare settings, including remote or resource-limited areas.
The blood grouping segment is expected to have the highest CAGR during the forecast period
Blood Grouping segment is expected to have the highest CAGR during the forecast period. Accurate blood typing and crossmatching are critical to prevent adverse reactions during transfusions. With advancements in technology and techniques for blood grouping, such as the introduction of automated systems and molecular testing methods, healthcare facilities can efficiently determine blood types and screen for irregular antibodies. This has significantly reduced the risk of transfusion reactions and improved patient outcomes. Additionally, the increasing demand for blood products due to rising surgical procedures, trauma cases, and chronic diseases has further propelled the regional growth of the Blood Transfusion Diagnostics Market.
Over the projected period, the North American area held the largest share due to rising disposable income, improved health infrastructure, rising health consciousness, and favorable reimbursement policies. The American Red Cross estimates that 16 million blood components are transfused annually in the United States. Additionally, this region's high rate of transfusion-transmitted infections and rising blood donation awareness are predicted to fuel market expansion.
Due to the rising number of patients with anemia which needs red blood cell transfusion for therapy, Asia Pacific is predicted to experience sustainable growth during the extended period, which is expected to drive up demand for blood transfusion diagnostics. Blood products and entire blood transfusions are in high demand in the area due to the rising prevalence of blood-related conditions such as hemophilia, cancer, thrombocytopenia, etc., and chronic kidney disease (CKD).
Key players in the market
Some of the key players in Blood Transfusion Diagnostics market include Abbott Laboratories, BAG Healthcare GmBH, Bio-Rad Laboratories, Inc, Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Grifols S.A., Hologic, Inc, Immucor, Inc, Ortho Clinical Diagnostics and Siemens Healthcare Private Limited.
In February 2023, MedGenome Labs launched FSHD1 genetic screening test to assess the genetic changes in patients at early stages to facilitate better treatment options. Various government initiatives and approvals are also encouraging players to enter the market.
In November 2022, Werfen entered into an agreement with TPG to acquire Immucor, Inc. Immucor, Inc., is a global company with a wide range of portfolio in transfusion diagnostics products. This will help the company to widen its product range by including the specialized diagnostics solution of Immucor, Inc.